Related Experiment Video
Updated: Jun 26, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Insulin for type 2 diabetes: choosing a second-line insulin regimen
1University of Birmingham and Heart of England NHS Foundation Trust, Birmingham, UK. anthony.barnett@heartofengland.nhs.uk
International Journal of Clinical Practice
|January 16, 2009
Summary
Choosing a second-line insulin regimen for type 2 diabetes is crucial when initial therapy fails. This guidance helps clinicians select the best option based on individual patient factors for optimal glycaemic control.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Existing guidance addresses initial insulin regimens for type 2 diabetes but lacks direction for second-line therapy.
- Glycaemic control often becomes unsatisfactory with first-line insulin, necessitating a switch to a more effective regimen.
Purpose of the Study:
- To develop pragmatic clinical guidance for selecting a second-line insulin regimen.
- Tailoring insulin therapy to individual patient needs after failure of initial treatment is the primary goal.
Main Methods:
- An expert panel formulated consensus-based guidance.
- Evidence synthesis and best clinical practice were considered, incorporating patient preferences, lifestyle, and functional capacity.
Main Results:
- Six patient-dependent factors were identified to guide second-line regimen choice.
- Three alternative regimens (twice-daily premixed, basal-plus, basal-bolus) were evaluated.
- An algorithm was developed to provide clinicians with pragmatic guidance, emphasizing lifestyle modifications.
Conclusions:
- Alternative insulin regimens offer distinct advantages and disadvantages.
- Appropriate selection of a second-line insulin regimen is vital for optimizing patient outcomes in type 2 diabetes.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...